Educational CME Accredited Programme

Prevention strategies for CV health

Chair:
  • Zeljko Reiner, Croatia
  • Alexandros Tselepis, Greece

Behaviour change in CVD prevention

Heike Englert, Münster, Germany

Can technology improve adherence to lifestyle?

Gil Blander, Boston, USA

Precision nutrition and CVD management

Jogchum Plat, Maastricht, The Netherlands

EAS have independently organised all matters related to this 90-minute programme, including content and presenters. We acknowledge financial support, in the form of an educational grant, received from industry in support of the programme.


Novel approaches to lipid lowering management

Chair:
  • Alberico L. Catapano, Italy
  • Marja-Riita Taskinen, Finland

What do we know so far about bempedoic acid?

Kausik Ray, London, UK

What is the landscape on lipid management today?

Lale Tokgözoglu, Ankara, Turkey

When do we need add on therapies to statin?

Ulrich Laufs, Leipzig, Germany

EAS have independently organised all matters related to this 90-minute programme, including content and presenters. We acknowledge financial support, in the form of an educational grant, received from industry in support of the programme.


Targeting lower LDL-C: When and how?

Chair:
  • Lale Tokgözoglu, Turkey
  • David Wood, UK

An update on the results of ODYSSEY outcomes

Gabriel Steg, Paris, France

Are the new EAS/ESC lipids goals reachable in clinical practice?

François Mach, Geneva, Switzerland

Risk stratification in very high risk patients is it of value?

Kausik Ray, London, UK

EAS have independently organised all matters related to this 90-minute programme, including content and presenters. We acknowledge financial support, in the form of an educational grant, received from industry in support of the programme.


The role of TG-rich lipoproteins in atherosclerosis

Chair:
  • Jan Boren, Sweden
  • Philippe Moulin, France

Case: Diabetic patient with MI - how to manage?

Dirk Mueller, Köln, Germany

Position of omega 3 in Guidelines (as second choice after statins)

Christie Ballantyne, Houston, USA

TG-rich lipoproteins as a risk factor

Ruth Frikke-Schmidt, Copenhagen, Denmark

The value of omega 3: from biology to clinical practice

Alberto Zambon, Padova, Italy

EAS have independently organised all matters related to this 90-minute programme, including content and presenters. We acknowledge financial support, in the form of an educational grant, received from industry in support of the programme.


Implementing guidelines: a patient-centered approach for daily practice

Chair:
  • Marat Ezhov, Russia
  • Paolo Parini, Sweden

Can combination aid adherence? (fixed dose, intolerance)

Michal Vrablik, Prague, Czech Republic

Difficult cases to reach goal: FH

Meral Kayikcioglu, Izmir, Turkey

Difficult cases to reach goal: Recurrent event on statin

Michel Farnier, Dijon, France

Translating science into guidance on the prevention of cardiovascular disease

Guy de Backer, Ghent, Belgium

Why and in whom is combination needed?

Luis Masana, Barcelona, Spain

EAS have independently organised all matters related to this 90-minute programme, including content and presenters. We acknowledge financial support, in the form of an educational grant, received from industry in support of the programme.


New ways to modulate TG metabolic pathways

Chair:
  • Christoph Binder, Austria
  • Arnold von Eckardstein, Switzerland

ANGPTL 3 Inhibition: recent clinical trials

Daniel Gaudet, Montreal, Canada

ANGPTL 3 what we have learned from genetics?

Marcello Arca, Rome, Italy

The Angiopoietin-like proteins, controlling lipoprotein metabolism

Sander Kersten, The Netherlands

EAS have independently organised all matters related to this 90-minute programme, including content and presenters. We acknowledge financial support, in the form of an educational grant, received from industry in support of the programme.


Lowering circulating PCSK9 to reduce LDL cholesterol: Current approaches

Chair:
  • Alberico L. Catapano, Italy
  • Lale Tokgözoglu, Turkey

Monoclonal antibody approaches targeting circulating PCSK9

Ulf Landmesser, Berlin, Germany

siRNA based approaches targeting hepatic synthesis of PCSK9

Kausik Ray, London, UK

The biology of PCSK9

Bertrand Cariou, Nantes, France

EAS have independently organised all matters related to this 90-minute programme, including content and presenters. We acknowledge financial support, in the form of an educational grant, received from industry in support of the programme.